Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The new openness provides opportunities for drug makers because it is no longer necessary to delegate all work to a Japanese partner, but the message is slow getting out.
You may also be interested in...
MHLW To Expand Drug Application Consultation Services July 1, But With A Price Tag For Industry
TOKYO - Japan's Ministry of Health, Labor and Welfare established a panel to improve the Pharmaceuticals and Medical Devices Agency's consultation services as one measure to eliminate Japan's drug and medical device lag, and the agency is expected to expand the range and number of consultations starting this year
MHLW To Expand Drug Application Consultation Services July 1, But With A Price Tag For Industry
TOKYO - Japan's Ministry of Health, Labor and Welfare established a panel to improve the Pharmaceuticals and Medical Devices Agency's consultation services as one measure to eliminate Japan's drug and medical device lag, and the agency is expected to expand the range and number of consultations starting this year
Parexel Chairman Josef von Rickenbach on Shifting CRO Models In Asia For Efficient Drug Development: An Interview With PharmAsia News (Part 2 of 2)
Roughly two-thirds of contract research organization Parexel's $1.1 billion 2010 revenue base was outside of the U.S., including about 12 percent in the Asia/Pacific region, and Chairman and CEO Josef von Rickenbach expects its share of APAC business to increase. In Tokyo for a day-long Parexel seminar to draw new clients in Japan, von Rickenbach and VP-Asia/Pacific Albert Liou spoke with PharmAsia News' Tokyo bureau about the company's shifting client base in Asia and the evolving partnership model in the CRO market in part one of this interview..